DB-OTO
Experimental gene therapy for a form of hearing loss
From Wikipedia, the free encyclopedia
DB-OTO is an experimental gene therapy for otoferlin-related hearing loss developed by Regeneron Pharmaceuticals. It is delivered via adeno-associated virus.[1][2][3][4][5][6]